53
Research Trials
20
Peer-reviewed publications
16
Clinical Conditions
This narrative review by Hyfe's R&D team makes the case that continuous cough monitoring (CCM), powered by acoustic AI, transforms cough from a subjective symptom into a quantifiable digital biomarker.
This ERS 2025 abstract from Hyfe's R&D team validates the wear-detection algorithm built into the Hyfe CoughMonitor smartwatch against participant-reported wear status across 418 person-hours of data in ten participants.
Authored by Hyfe's R&D team, this review synthesizes work presented at the European Respiratory Society Congress 2025 and argues that objective cough monitoring has crossed a practical threshold, moving from experimental technique to deployable clinical endpoint.
This study asked whether the core components of BCST could be embedded in a digital therapeutic and paired with continuous, objective cough monitoring inside the CoughPro app.
Risk scores are used throughout medical care to guide treatments, allocate resources, and control outbreaksof disease. Though valuable, most risk scores are limited by their basis in aging datasets and their use withpatients in single, time-constrained consultations. Mobile health could collect longitudinal or even continuousdata on patient health. Automated, dynamic, and real-time risk profiles could trigger earlier interventions, improveclinical outcomes, guide resource distribution, and preempt outbreaks.
Dynamic risk profiles hold enormouspotential for global health, and smartphones are now uniquely equipped and positioned to unlock that potential.We identify cough, an information-rich and readily monitored syndrome, as the symptom that will pioneer ’smartrisk profiling’ systems, prove their value in alleviating the global burden of respiratory disease, and usher in anew era of proactive mobile health.
